MENU
The partnership between Clinical Trials Unit (CTU) in the University of Kelaniya, and RemediumOne was established with the primary objective of creating a centre of excellence for epidemiological and clinical research in Sri Lanka.
Our clinical research portfolio demonstrates diverse therapeutic expertise, strategically focused on addressing both global health burdens and regional medical needs.
Cardiology is our largest area of expertise, where we lead clinical trials in hypertension, heart failure, and landmark polypill studies that have been guideline-changing at the global level. We have extensive experience in progressive renal conditions, with a particular focus on Immunoglobulin A Nephropathy (IgAN), glomerular kidney diseases with proteinuria, and the management of chronic kidney disease (CKD). Our capabilities also extend across a range of neurological and psychiatric disorders, including stroke, neurodegenerative diseases, bilateral blepharospasm (BEB), schizophrenia, and depression.
Infectious diseases have been a major focus since our earliest landmark trial in snakebite antivenom, which addressed one of the world’s most neglected tropical diseases. Since then, we have expanded into dengue diagnostics, COVID-19 therapies, and pneumonia research, contributing evidence that is directly relevant to regional and global public health priorities. We have also successfully conducted major trials in gestational diabetes, type 2 diabetes, and dyslipidemias, and continue to expand our expertise in endocrine and metabolic disorders.
With over a decade of experience across 70+ indications, we still remain to generate high-quality and impactful research evidence that improves patient care and informs healthcare policy worldwide.
